Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.

about

Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.

Item

http://www.wikidata.org/entity/Q47567739

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@en

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@nl

type

Item

label

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@en

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@nl

prefLabel

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@en

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@nl

P1476

Random non-fasting C-peptide t ...... at high risk of hypoglycaemia.

@en

P2093

Anita V Hill

http://www.w3.org/2001/XMLSchema#string

Beverley M Shields

http://www.w3.org/2001/XMLSchema#string

Bridget A Knight

http://www.w3.org/2001/XMLSchema#string

P2860

Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay

Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic eva

Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms.

Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.

Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.

Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control.

Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes.

Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin.

EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature.

Low levels of C-peptide have clinical significance for established Type 1 diabetes.

P2888

s00125-017-4449-2

P304

66-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-017-4449-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28983693

http://www.w3.org/2001/XMLSchema#string

P921

hypoglycemia

type-2 diabetes

P932

6002965

http://www.w3.org/2001/XMLSchema#string